News
Good news keeps coming! Wanbangde Pharmaceutical Group has proudly earned two prestigious awards: "Top 100 Chinese Pharmaceutical Manufacturers 2022-2023" and "Top 50 Fast-Growing Companies in China's Pharmaceutical Industry"!
Date:
02 Aug,2023
Introduction: From July 3 to 5, the "15th China Pharmaceutical Industry Development Summit Forum and Harbin New Area Promotion Event," featuring the unveiling of the "2022-2023 China's Most Influential Pharmaceutical Industry Rankings," was held in Harbin. The event was jointly hosted by the All-China Federation of Industry and Commerce Pharmaceutical Industry Chamber of Commerce, the Heilongjiang Provincial Federation of Industry and Commerce, and the Heilongjiang Provincial Development and Reform Commission.
The conference, themed "Promoting High-Quality Development of the Industry and Revitalizing Northeast China's Pharmaceutical Sector," featured insightful discussions and policy analyses from various perspectives on industry trends and hot topics. Against the backdrop of the "Healthy China" initiative, participants came together to explore both the opportunities and challenges facing the pharmaceutical industry.
On the evening of July 4, the highly anticipated "2022-2023 China Pharmaceutical Industry's Most Influential Ranking" was officially unveiled. Wanbangde Pharmaceutical Group Co., Ltd. has proudly earned two prestigious awards: "Top 100 Chinese Pharmaceutical Manufacturers 2022-2023" and "Top 50 Fast-Growing Companies in China's Pharmaceutical Industry 2022-2023"!
Notably, this marks the first time Wanbangde Pharmaceutical Group has earned a spot among the "Top 100 Chinese Pharmaceutical Manufacturers." It also highlights the company’s remarkable achievement, as Wanbangde Pharmaceutical Group has once again been recognized—this time as a double honor—after previously making the "2019 and 2021 China Pharmaceutical Industry Growth Top 50" list.
As a prestigious brand event in China's pharmaceutical industry, the selection of China's Most Influential Pharmaceutical Industry Rankings has been held for ten consecutive years. It is renowned for its comprehensive coverage of the entire industry chain, strong representativeness, high participation, and significant influence. Adhering to the principles of open solicitation, objective data analysis, rigorous screening, and impartial evaluation, the selection process invites top-tier domestic experts to form an expert panel. Collaborating with several well-known media outlets across the country, this initiative carefully curates annual lists that have become one of the most influential and trusted rankings in China's pharmaceutical sector.
As 2023 reaches its halfway point, Wanbangde Pharmaceutical Group continues to make steady progress while steadily earning numerous accolades. These honors come with a sense of responsibility and commitment. Moving forward, Wanbangde will leverage its leading role to seize opportunities, foster collaboration, and align itself with the new-era requirements of "two healthy" principles. By pursuing a specialized, innovative, and distinctive development path, the group remains dedicated to deepening its commitment to health initiatives on this new journey—striving to become a pioneer in shaping the country’s new development paradigm, a driving force behind China’s modernization efforts, and a steadfast advocate for the Healthy China initiative.
Related Recommendations